

Online Resource 4

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy

Journal: Breast Cancer Research and Treatment

Authors: A.F. de Groot¹, E.J. Blok^{1,2}, A. Charehbili^{1,2}, C.C. Engels², V.T.H.B.M. Smit³, N.G. Dekker-Ensink², H. Putter⁴, E. Meershoek - Klein Kranenbarg², C.J.H. van de Velde², G.J. Liefers², J.W.R. Nortier¹, P.J.K. Kuppen², S.H. van der Burg¹, J.R. Kroep¹

Departments of Medical Oncology¹, Surgery², Pathology³, Statistics⁴, Leiden University Medical Center, Leiden, The Netherlands

Corresponding author: Judith R. Kroep, M.D., Ph.D. (j.r.kroep@lumc.nl)

Online Resource 4 Immune marker-based analyses stratified on HR status and menopausal status

		CD8+ CTLs				P-value	FoxP3+ Tregs				P-value	CD68+ TAMs				P-value	HLA class 1 status				P-value
		Low (< median)		High (> median)			Low (< median)		High (> median)			Low (< median)		High (> median)			Loss + downregulation		Expression		
		pCR		pCR			pCR		pCR			pCR		pCR			pCR		pCR		
		N	%	N	%		N	%	N	%		N	%	N	%		N	%	N	%	
HR status	HR- (TNBC)	1	10.0%	6	42.9%	0.17	1	20.0%	6	31.6%	1.00	4	36.4%	4	33.3%	1.00	0	0.0%	7	30.4%	0.55
	HR+	3	4.5%	8	12.9%	0.09	6	8.2%	3	5.7%	0.73	5	7.4%	5	7.6%	1.00	2	3.7%	9	10.0%	0.21
Menopausal status	Pre	2	4.8%	7	15.9%	0.16	3	7.3%	3	7.7%	1.00	6	12.2%	2	5.6%	0.46	1	3.4%	7	11.1%	0.43
	Peri	0	0.0%	2	50.0%	1.00	1	50.0%	2	50.0%	1.00	1	20.0%	1	100.0%	0.33	1	50.0%	2	40.0%	1.00
	Post	1	3.0%	5	18.5%	0.08	2	5.9%	4	14.3%	0.40	2	8.0%	5	12.8%	0.70	0	0.0%	6	14.0%	0.08

Loss or downregulation of HLA class 1 is defined as <5% of tumor cells staining positive for HCA2 and HC10 (loss), or either HCA2 or HC10 (downregulation).

Expression of HLA class 1 is defined as ≥5% of tumor cells staining positive for HCA2 and HC10. P-values represent Chi-square or Fisher's exact tests. *CTLs* cytotoxic T-cells, *HR* hormone receptor, *pCR* pathological complete response, *TAMs* tumor-associated macrophages, *TNBC* triple negative breast cancer, *Tregs* regulatory T-cells